Nested (Ossifying) Stromal Epithelial Tumor of the Liver: Case Report

2009 ◽  
Vol 12 (3) ◽  
pp. 233-236 ◽  
Author(s):  
Karen Meir ◽  
Alexander Maly ◽  
Victoria Doviner ◽  
Eitan Gross ◽  
Michael Weintraub ◽  
...  
Keyword(s):  
Needle Biopsy ◽  
English Language ◽  
Malignant Potential ◽  
Liver Mass ◽  
Uncertain Malignant Potential ◽  
Cytokeratin 18 ◽  
Epithelial Tumor ◽  
Antenatal Ultrasound ◽  
Language Literature

Nested stromal-epithelial tumor (NSET) of the liver is an extremely rare primary hepatic tumor with uncertain malignant potential. To date, only 11 cases have been described. We describe the case of a 2 1/2-year-old girl with an incidental liver mass. The mass was discovered on follow-up abdominal imaging for asymptomatic hydronephrosis diagnosed on antenatal ultrasound. Needle biopsy showed a mixed stromal and epithelial process in a nested pattern, with foci of ossification and no significant pleomorphism or necrosis. The nest cells stained with WT-1, cytokeratin 18, and CD56. Ossifying stromal epithelial tumor of the liver was strongly suspected. The findings were confirmed in the subsequent partial hepatectomy specimen. To our knowledge, this is the 12th case of NSET in the English-language literature and the 3rd case of NSET associated with genitourinary system abnormalities. Possible associations with dysregulated WT-1 expression are discussed.

scholarly journals Minimally invasive treatment options to borderline ovarian tumors

2016 ◽  
Author(s):  
Punita Bhardwaj ◽  
T. K. Das ◽  
S. Batra ◽  
Keyword(s):  
Early Stage ◽  
Treatment Options ◽  
Malignant Potential ◽  
Ovarian Tumors ◽  
Conservative Approach ◽  
Uncertain Malignant Potential ◽  
Invasive Treatment ◽  
Younger Women ◽  
Borderline Ovarian Tumors

Borderline Ovarian tumors are tumors of uncertain malignant potential. They have favour able prognosis. They occur in younger women and present at an early stage. They are difficult to diagnose preoperatively as macroscopic picture is a combination of benign and invasive ovarian tumors. Over the years surgical treatment has changed from radical to conservative approach without overlooking oncologic safety. Follows up is essential. Prolonged follow up (>10 yrs) is required because of later recurrences. Special attention is to be paid to the conserved ovary in follow up.

scholarly journals Nasal Cavity Ossifying Fibrosarcoma: An Unusual Fibro-Osseous Neoplasm

2010 ◽  
Vol 89 (11) ◽  
pp. E1-E3 ◽  
Author(s):  
Yadiel A. Alameda ◽  
Carlos Perez-Mitchell ◽  
José M. Busquets
Keyword(s):  
Soft Tissue ◽  
Nasal Cavity ◽  
English Language ◽  
Clinical Presentation ◽  
Soft Tissue Mass ◽  
Histopathologic Examination ◽  
Left Nasal Cavity ◽  
Tissue Mass ◽  
Language Literature

We describe the case of a 65-year-old woman who presented with left nasal obstruction. Clinical and radiographic examinations revealed the presence of a soft-tissue mass that had obliterated the left nasal cavity. The mass was completely excised via an endoscopic approach. Histopathologic examination identified the tumor as an ossifying fibrosarcoma. The patient recovered uneventfully and remained free of disease at the 2-year postoperative follow-up. To the best of our knowledge, no case of an ossifying fibrosarcoma of the nasal cavity has been previously reported in the English-language literature. We discuss the features of this case and the clinical presentation, diagnosis, and management of fibrosarcomas of the nasal cavity and paranasal sinuses.

Incidental Prostatic Stromal Tumor of Uncertain Malignant Potential (STUMP): Histopathological and Immunohistochemical Findings

2012 ◽  
Vol 79 (1) ◽  
pp. 65-68 ◽  
Author(s):  
Ettore De Berardinis ◽  
Gian Maria Busetto ◽  
Gabriele Antonini ◽  
Riccardo Giovannone ◽  
Mariarosaria Di Placido ◽  
...  
Keyword(s):  
Prostate Gland ◽  
Digital Rectal Examination ◽  
Radical Retropubic Prostatectomy ◽  
Malignant Potential ◽  
Stromal Tumor ◽  
Uncertain Malignant Potential ◽  
Transperineal Prostate Biopsy ◽  
Stromal Sarcoma ◽  
Long Term Follow Up

Stromal prostate tumors are rare neoplastic proliferative lesions that have been classified into prostatic stromal tumor of uncertain malignant potential (STUMP) and prostatic stromal sarcoma (SS) based on these criteria: stromal cellularity, presence of mitotic figures, necrosis, and stromal overgrowth. A prostatic stromal tumor of uncertain malignant potential (STUMP) is a non-epithelial, mesenchymal spindle-cell tumor that can be classified as a specialized stromal tumor of the prostate. STUMPs have the capability to diffusely infiltrate the prostate gland and extend into adjacent tissues. Furthermore, they often recur and this is why they are considered as neoplastic entities. STUMPs usually tend to be not aggressive, but occasional cases have been reported with an extension into adjacent tissues. A few cases develop a sarcomatous dedifferentiation. A 67-year-old male referred to the Department of Urology, Sapienza Rome University, with acute urinary retention (AUR) and bladder overdistention. Digital rectal examination (DRE) showed the presence of a severe prostatic hyperplasia and a transvesical prostatic adenomectomy (TVPA) was performed. The pathological evaluation performed at the Department of Pathology, Sapienza Rome University, revealed an incidental diagnosis of prostatic STUMP. The patient's follow-up is made every year with transrectal ultrasonography and nuclear magnetic resonance with spectroscopy, and every two years with a transperineal prostate biopsy to exclude a progression to a stromal sarcoma. After 5 years of follow-up the STUMP is still detectable but there is no sign of sarcoma. As a result of its relative rarity and lack of long-term follow-up, the prognosis of STUMP is unclear. Therapy varies from a wait-and-see approach to a radical retropubic prostatectomy.

Adrenocortical neoplasm of uncertain malignant potential with a myelolipomatous component

2020 ◽  
Vol 13 (6) ◽  
pp. e234591
Author(s):  
Adithya Balasubramanian ◽  
Jason Scovell ◽  
Adam E Dowell ◽  
Wesley Mayer
Keyword(s):  
Adrenal Mass ◽  
Benign Neoplasm ◽  
Malignant Potential ◽  
Uncertain Malignant Potential ◽  
The Third ◽  
Potentially Malignant ◽  
Indeterminate Lesion ◽  
Fatty Component ◽  
Oncocytic Neoplasm

Macroscopic fat inside an adrenal lesion on CT is pathognomonic for myelolipoma, a benign neoplasm. Without macroscopic fat, it can be difficult to discern the nature of an indeterminate adrenal mass on imaging. One possible diagnosis for an indeterminate lesion without macroscopic fat is an adrenal oncocytic neoplasm (AON). Despite its typical benign presentation cases of malignant AON have been reported. Patients with malignant AON are often not surgical candidates and survival for unresected disease is 20%–35%. We present the third report of an AON of uncertain malignant potential (AONUMP) associated with a macroscopic fatty component with the largest reported size and longest duration of follow-up in the literature. This report details diagnostic and therapeutic challenges posed by AONUMP. This case highlights how pathognomonic radiographical findings associated with benign myelolipoma might mask rare, potentially malignant, lipomatous tumours.

scholarly journals Application of the Milan System for Reporting Salivary Gland Cytopathology: A Retrospective 12-Year Bi-institutional Study

2019 ◽  
Vol 151 (6) ◽  
pp. 613-621 ◽  
Author(s):  
Howard H Wu ◽  
Fatimah Alruwaii ◽  
Bao-Rung Zeng ◽  
Harvey M Cramer ◽  
Chiung-Ru Lai ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Benign Neoplasm ◽  
Malignant Potential ◽  
Salivary Gland Neoplasm ◽  
Uncertain Malignant Potential ◽  
Risk Of Malignancy ◽  
Predictive Rate ◽  
Sensitivity Specificity ◽  
Undetermined Significance

Abstract Objectives Multi-institutional studies are required for the validation of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC). Methods A total of 1,560 fine-needle aspirations of the salivary glands were retrieved from two institutions for a 12-year period. The diagnoses were reclassified based on the MSRSGC. Risk of malignancy (ROM) for each category was calculated based on 694 histologic follow-up cases. Results The ROM for each category was: 18.3% for nondiagnostic, 8.9% for nonneoplastic, 37.5% for atypia of undetermined significance (AUS), 2.9% for benign neoplasm, 40.7% for salivary gland neoplasm of uncertain malignant potential (SUMP), 100% for suspicious for malignancy, and 98.3% for malignant. The sensitivity, specificity, positive predictive rate, and negative predictive rates were 89%, 99%, 98%, and 96%, respectively. Conclusions The results of the current study are in keeping with the MSRSGC. The indeterminate categories of AUS and SUMP showed intermediate ROMs at 37.5% and 40.7%, respectively.

Clinical outcome of atypical uterine smooth muscle tumors

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15028-15028 ◽  
Author(s):  
B. Pothuri ◽  
S. M. Kehoe ◽  
T. Wright ◽  
T. Herzog
Keyword(s):  
Smooth Muscle ◽  
Clinical Outcome ◽  
Retrospective Chart Review ◽  
Malignant Potential ◽  
Low Grade ◽  
Uncertain Malignant Potential ◽  
Histologic Diagnosis ◽  
Cellular Atypia ◽  
Smooth Muscle Tumors

15028 Background: Smooth muscle tumors of uncertain malignant potential (STUMP) and atypical leiomyomas have increased mitotic activity, cellular atypia and necrosis but the degree is less than that used to define uterine leiomyosarcomas. Our objective is to evaluate the clinical outcome of patients with uterine masses histologically defined as smooth muscle tumors of uncertain malignant potential or atypical leiomyomas. Methods: A thorough search of our institution’s pathology database from 1990 to 2005 was performed. A retrospective chart review was performed to obtain initial and subsequent treatments, documented recurrences and clinical outcomes. Pathology reports and slides were reviewed and the presence of atypia, necrosis and number of mitosis was recorded. Statistical analysis was performed by Student’s T-test. Results: Eighteen patients with a histologic diagnosis of atypical leiomyoma were identified with 14 STUMP, 2 bizarre leiomyomas, 1 myxoid and 1 mitotically active leiomyoma. The mean age of these patients was 41.8 years (range: 25–77) and was significantly younger than those with leiomyosarcoma (mean age was 54 years, p < 0.001). The histologic characteristics of the tumors included the presence of atypia at 50%, necrosis at 82% and mitoses at 94%. The rate of necrosis and number of mitosis was significantly less in the atypical group as compared to the leiomyosarcoma group (p values < 0.05). However the rate of cellular atypia was not statistically different between the two groups. The median follow-up period was 25 months, range 1–138 months. One of the eighteen patients developed a pelvic and pulmonary recurrence at which time a low grade leiomyosarcoma was diagnosed. The recurrence occurred 32 months after the initial diagnosis of a mitotically active leiomyoma. Sixteen patients demonstrated no recurrence or metastatic disease at the time of follow-up. Conclusions: Atypical leiomyomas appear to be diagnosed in younger women which leads to challenging treatment issues involving fertility preservation. While these tumors generally behave in a benign fashion, they have histologic characteristics that may allow for progression or recurrence. Close follow-up is warranted for patients who are diagnosed with atypical leiomyomas and smooth muscle tumors of uncertain malignant potential. No significant financial relationships to disclose.

A Systematic Review of the Literature on Evaluative Studies of Tonsillectomy and Adenoidectomy

PEDIATRICS ◽  
1976 ◽  
Vol 57 (3) ◽  
pp. 401-407
Author(s):  
W. Shaikh ◽  
E. Vayda ◽  
W. Feldman
Keyword(s):  
United States ◽  
Study Design ◽  
English Language ◽  
Randomized Study ◽  
The United States ◽  
English Language Literature ◽  
Considerable Controversy ◽  
The Cost ◽  
Language Literature

Although tonsillectomy and adenoidectomy (T and A) is frequently performed (indeed, it is the commonest surgical procedure done in North America1,2) considerable controversy persists regarding its effectiveness. In 1971, 161,301 T and A's were performed in Canada at an estimated cost of close to 25.6 million dollars.3 In the United States in 1968 more than 1 million T and A's were performed.4 Assuming the cost per T and A to be similar to the costs in Canada, around $150 million were spent on this procedure in the United States in that year. The purpose of this study is to review the English language literature pertaining to evaluation of T and A with particular emphasis on an assessment of the scientific merit of studies which have attempted to determine the efficacy of this procedure. See Table in the PDF File METHOD Studies evaluating the results of T and A in the English language literature for the past 50 years5-33 were evaluated according to the following parameters: study design, sampling, completeness of description of illness and therapy, and precision of follow-up. Those studies which were most objective were awarded the highest points in each parameter. Conversely, studies which were purely descriptive or poorly documented received the fewest points. The maximum number of points which a randomized, prospective, well-documented study could obtain was 34 points. Table I shows the distribution of maximum scores in the various categories. For the parameter of study design, points were awarded as shown in Table II. The highest score was given to a randomized study and the lowest to a descriptive one.

Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases

2020 ◽  
pp. 1-9
Author(s):  
Qi Shen ◽  
Zhaohui Zhou ◽  
Zhenhua Liu ◽  
Shuai Hu ◽  
Zhiyong Lin ◽  
...  
Keyword(s):  
Disease Progression ◽  
Rare Disease ◽  
Subgroup Analysis ◽  
Specific Antigen ◽  
Malignant Potential ◽  
Stromal Tumor ◽  
Uncertain Malignant Potential ◽  
Stromal Sarcoma ◽  
The Mean

<b><i>Introduction:</i></b> Prostatic stromal tumor of uncertain malignant potential (STUMP) is a rare disease that may coexist with prostate stromal sarcoma (PSS). We aimed to analyze the histological and clinical features of STUMP. <b><i>Methods:</i></b> Twenty-three patients diagnosed with STUMP from 2008 to 2019 were included. Clinicopathological and follow-up information was collected. In the subgroup analysis, we divided the patients into a pure STUMP group (<i>N</i> = 18) and a mixed STUMP (STUMP coexisting with PSS) group (<i>N</i> = 5). Student’s <i>t</i> test was used to compare the 2 groups. <b><i>Results:</i></b> Patients had a mean age of 55.5 ± 19.4 years and an average follow-up time of 42.3 months. The mean prostate volume was 109.2 ± 73.5 cm<sup>3</sup>, and the mean prostate-specific antigen was 8.03 ± 10.5 ng/mL. In the subgroup analysis, 16.7% (2/12) of pure STUMP patients had disease progression, while 100% (3/3) of mixed STUMP patients suffered from recurrence. Compared with the pure STUMP group, the mixed STUMP group was younger (37.2 vs. 60.6 years, <i>p</i> = 0.013) and had lower expression of estrogen receptor and progesterone receptor (<i>p</i> = 0.004 and <i>p</i> &#x3c; 0.001, respectively). <b><i>Conclusion:</i></b> STUMP is a rare disease with a relatively good prognosis. However, there is still a possibility of disease progression or coexistence with stromal sarcoma. Timely diagnosis and regular monitoring may be helpful in improving treatment outcomes.

Sign in / Sign up

Export Citation Format

Share Document